Skip to content

The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function

The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00627068
Enrollment
60
Registered
2008-02-29
Start date
2007-07-31
Completion date
2010-12-31
Last updated
2011-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

cardiovascular, vasodilation, endothelium, Subjects with high cardiovascular risk

Brief summary

Our main hypothesis is that EPC function is impaired in some populations with high cardiovascular risk as a result of reduced eNOS-dependent NO production.

Detailed description

To determine if a correlation exists between EPC function and eNOS-dependent NO production in EPCs from populations with high versus low cardiovascular risk: 1. High and low cardiovascular risk subjects will be identified based on age or history of cardiovascular disease. Endothelial function will be measured by ultrasound. 2. EPCs will be isolated from peripheral blood of these subjects. EPC function will be assessed by measuring adhesion to endothelium, migration, proliferation, and differentiation, and compared to their expression and activity of eNOS.

Interventions

None listed

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Willing and able to give written informed consent and comply with study requirements * Adult of 18 years or older * Subjects willing to provide blood and tissue samples

Exclusion criteria

* Failure to give informed consent. * Those unable to consent for themselves. * Those who cannot read English. * Patients on Viagra, Levitra, or Cialis * Patients with malignant disease * Patients with hematological abnormalities * Patients with fevers of unknown origin * Severe comorbidity or alcohol/drug dependence * Women who are post-menopausal and on hormone replacement therapy, or premenopausal and on birth control pills (premenopausal women will be screened verbally and then by assay of LH and FSH levels in blood samples to identify women in the follicular phase of their menstrual cycle, to reduce variability)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026